A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 35/14 (2006.01) A61K 38/16 (2006.01) A61K 38/19 (2006.01) A61K 38/20 (2006.01) A61K 39/395 (2006.01) C12N 5/06 (2006.01) A61K 35/12 (2006.01) A61K 38/00 (2006.01)
Patent
CA 2184352
Methods have been discovered for treating residual disease following removal of most or a substantial fraction of malignant cells from a cancer patient. An autologous stem cell transplant is performed on the patient. Following partial hematopoiesis recovery, the patient is infused with allogeneic peripheral blood lymphocytes, either alone or in combination with in vivo or in vitro T-cell activation. The infused allogeneic lymphocytes engender and anti-malignant cell response.
On a découvert des méthodes de traitement de pathologies résiduelles consécutives à la suppression de la plupart ou d'une grande partie des cellules malignes chez un patient souffrant de cancer. On procède à la transplantation de cellules souches autologues sur la patient. Après une reprise partielle de l'hématopoïèse, on administre au patient par perfusion des lymphocytes allogènes du sang périphérique, seuls ou combinés avec une activation <u>in</u> <u>vivo</u> ou <u>in</u> <u>vitro</u> des lymphocytes T. Les lymphocytes allogéniques administrés par perfusion induisent une réponse anti-cellules malignes.
Baxter International Inc.
Hadasit Medical Research Services And Development Ltd.
Sim & Mcburney
LandOfFree
Immunotherapy of cancer with allogeneic lymphocytes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunotherapy of cancer with allogeneic lymphocytes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunotherapy of cancer with allogeneic lymphocytes will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1830769